Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

The discriminative stimulus effects of epibatidine in C57BL/6J mice.

de Moura FB, Hiranita T, McMahon LR.

Behav Pharmacol. 2020 Mar 23. doi: 10.1097/FBP.0000000000000555. [Epub ahead of print]

PMID:
32209809
2.

More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Moerke MJ, McMahon LR, Wilkerson JL.

Pharmacol Rev. 2020 Apr;72(2):527-557. doi: 10.1124/pr.119.018028. Review.

PMID:
32205338
3.

Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.

Wilkerson JL, Deba F, Crowley ML, Hamouda AK, McMahon LR.

Neuropharmacology. 2020 Feb 12;168:108008. doi: 10.1016/j.neuropharm.2020.108008. [Epub ahead of print] Review.

PMID:
32113032
4.

Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-β-erythroidine in nicotine-tolerant mice.

de Moura FB, Wilkerson JL, McMahon LR.

Brain Behav. 2020 Feb 24:e01581. doi: 10.1002/brb3.1581. [Epub ahead of print]

5.

Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery.

Navaratne PV, Wilkerson JL, Ranasinghe KD, Semenova E, Felix JS, Ghiviriga I, Roitberg A, McMahon LR, Grenning AJ.

ChemMedChem. 2020 Feb 15. doi: 10.1002/cmdc.202000025. [Epub ahead of print]

PMID:
32061146
6.

Hydrolysis and enzymatic degradation of Novichok nerve agents.

Harvey SP, McMahon LR, Berg FJ.

Heliyon. 2020 Jan 7;6(1):e03153. doi: 10.1016/j.heliyon.2019.e03153. eCollection 2020 Jan.

7.

Pharmacological characterization of mitragynine, the primary constituent in Kratom, as a potential medication for opioid use disorder.

McMahon LR, Hiranita T, Wilkerson JL, Oyala JFL, McCurdy CR.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.012. Epub 2019 Oct 17. No abstract available.

PMID:
31963089
8.

Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.

King TI, Sharma A, Kamble SH, León F, Berthold EC, Popa R, Cerlati O, Prentice BM, McMahon LR, McCurdy CR, Avery BA.

J Pharm Biomed Anal. 2020 Feb 20;180:113019. doi: 10.1016/j.jpba.2019.113019. Epub 2019 Dec 5.

PMID:
31838282
9.

Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.

Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, León F, Hiranita T, Avery BA, McMahon LR, McCurdy CR.

J Med Chem. 2020 Jan 9;63(1):433-439. doi: 10.1021/acs.jmedchem.9b01465. Epub 2019 Dec 27.

PMID:
31834797
10.

Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.

Kamble SH, Sharma A, King TI, Berthold EC, León F, Meyer PKL, Kanumuri SRR, McMahon LR, McCurdy CR, Avery BA.

Toxicol Lett. 2020 Feb 1;319:148-154. doi: 10.1016/j.toxlet.2019.11.005. Epub 2019 Nov 7.

PMID:
31707106
11.

The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Wilkerson JL, Felix JS, Restrepo LF, Ansari MI, Coop A, McMahon LR.

J Pharmacol Exp Ther. 2019 Sep;370(3):380-389. doi: 10.1124/jpet.118.255844. Epub 2019 Jun 24.

PMID:
31235534
12.

Kratom policy: The challenge of balancing therapeutic potential with public safety.

Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D.

Int J Drug Policy. 2019 Aug;70:70-77. doi: 10.1016/j.drugpo.2019.05.003. Epub 2019 May 16.

13.

The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.

Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, Wilkerson JL.

Psychopharmacology (Berl). 2019 Sep;236(9):2725-2734. doi: 10.1007/s00213-019-05247-7. Epub 2019 May 17.

PMID:
31098655
14.

Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.

Wilkerson JL, Schulze DR, McMahon LR.

PLoS One. 2019 Mar 12;14(3):e0209947. doi: 10.1371/journal.pone.0209947. eCollection 2019.

15.

Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.

Cunningham CS, Moerke MJ, McMahon LR.

Pharmacol Biochem Behav. 2019 Apr;179:27-33. doi: 10.1016/j.pbb.2019.02.002. Epub 2019 Feb 6.

PMID:
30738085
16.

Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.

Moerke MJ, McMahon LR.

Drug Dev Ind Pharm. 2019 May;45(5):861-867. doi: 10.1080/03639045.2019.1578787. Epub 2019 Feb 22.

PMID:
30712397
17.

Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.

McMahon LR.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):189-195. doi: 10.1080/17512433.2019.1570844. Epub 2019 Jan 24. Review.

18.

Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.

de Moura FB, McMahon LR.

Behav Pharmacol. 2019 Aug;30(5):412-421. doi: 10.1097/FBP.0000000000000452.

PMID:
30398980
19.

Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.

Moerke MJ, McMahon LR.

Exp Clin Psychopharmacol. 2018 Dec;26(6):541-548. doi: 10.1037/pha0000226. Epub 2018 Aug 13.

20.

An OPAA enzyme mutant with increased catalytic efficiency on the nerve agents sarin, soman, and GP.

Bae SY, Myslinski JM, McMahon LR, Height JJ, Bigley AN, Raushel FM, Harvey SP.

Enzyme Microb Technol. 2018 May;112:65-71. doi: 10.1016/j.enzmictec.2017.11.001. Epub 2017 Nov 21.

PMID:
29499783
21.

Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.

Hruba L, McMahon LR.

J Pharmacol Exp Ther. 2017 Aug;362(2):278-286. doi: 10.1124/jpet.117.240572. Epub 2017 May 22.

22.

The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.

de Moura FB, McMahon LR.

Psychopharmacology (Berl). 2017 Mar;234(5):781-792. doi: 10.1007/s00213-016-4514-4. Epub 2016 Dec 27.

23.

The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Moerke MJ, Zhu AZ, Tyndale RF, Javors MA, McMahon LR.

Neuropharmacology. 2017 Apr;116:9-17. doi: 10.1016/j.neuropharm.2016.12.003. Epub 2016 Dec 8.

24.

Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Cunningham CS, Moerke MJ, Javors MA, Carroll FI, McMahon LR.

Br J Pharmacol. 2016 Dec;173(24):3454-3466. doi: 10.1111/bph.13635. Epub 2016 Nov 6.

25.

Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.

McMahon LR.

Drug Alcohol Depend. 2016 Aug 1;165:87-93. doi: 10.1016/j.drugalcdep.2016.05.016. Epub 2016 Jun 3.

26.

Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.

Moerke MJ, de Moura FB, Koek W, McMahon LR.

Eur J Pharmacol. 2016 Sep 5;786:169-178. doi: 10.1016/j.ejphar.2016.05.032. Epub 2016 May 27.

27.
28.

The rise (and fall?) of drug discrimination research.

McMahon LR.

Drug Alcohol Depend. 2015 Jun 1;151:284-8. No abstract available.

29.

Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.

Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 Aug;354(2):111-20. doi: 10.1124/jpet.115.222851. Epub 2015 May 21.

30.

Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.

Hruba L, Seillier A, Zaki A, Cravatt BF, Lichtman AH, Giuffrida A, McMahon LR.

J Pharmacol Exp Ther. 2015 May;353(2):261-8. doi: 10.1124/jpet.115.222836. Epub 2015 Feb 24.

31.

The discriminative stimulus effects of mecamylamine in nicotine-treated and untreated rhesus monkeys.

Cunningham CS, Moerke MJ, McMahon LR.

Behav Pharmacol. 2014 Aug;25(4):296-305. doi: 10.1097/FBP.0000000000000054.

32.

JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.

Rodriguez JS, McMahon LR.

Eur J Pharmacol. 2014 Oct 5;740:151-9. doi: 10.1016/j.ejphar.2014.06.023. Epub 2014 Jun 24.

33.

Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Rodriguez JS, Cunningham CS, Moura FB, Ondachi P, Carroll FI, McMahon LR.

Psychopharmacology (Berl). 2014 Dec;231(23):4455-66. doi: 10.1007/s00213-014-3589-z. Epub 2014 May 7.

34.

Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure.

Ginsburg BC, Hruba L, Zaki A, Javors MA, McMahon LR.

Drug Alcohol Depend. 2014 Jun 1;139:1-8. doi: 10.1016/j.drugalcdep.2014.02.696. Epub 2014 Mar 19.

35.

The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.

Hruba L, McMahon LR.

Eur J Pharmacol. 2014 Mar 15;727:35-42. doi: 10.1016/j.ejphar.2014.01.041. Epub 2014 Jan 30.

36.

Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Cunningham CS, McMahon LR.

Psychopharmacology (Berl). 2013 Jul;228(2):321-33. doi: 10.1007/s00213-013-3037-5. Epub 2013 Mar 14.

37.

Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.

Hruba L, Ginsburg BC, McMahon LR.

J Pharmacol Exp Ther. 2012 Sep;342(3):843-9. doi: 10.1124/jpet.112.196444. Epub 2012 Jun 20.

38.

Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice.

Gould GG, Seillier A, Weiss G, Giuffrida A, Burke TF, Hensler JG, Rock C, Tristan A, McMahon LR, Salazar A, O'Connor JC, Satsangi N, Satsangi RK, Gu TT, Treat K, Smolik C, Schultz ST.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):260-9. doi: 10.1016/j.pnpbp.2012.04.011. Epub 2012 Apr 21.

39.

Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.

Cunningham CS, Javors MA, McMahon LR.

J Pharmacol Exp Ther. 2012 Jun;341(3):840-9. doi: 10.1124/jpet.112.193078. Epub 2012 Mar 21.

40.

Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.

Schulze DR, Carroll FI, McMahon LR.

Psychopharmacology (Berl). 2012 Aug;222(3):425-38. doi: 10.1007/s00213-012-2661-9. Epub 2012 Feb 29.

41.

Purity of synthetic cannabinoids sold online for recreational use.

Ginsburg BC, McMahon LR, Sanchez JJ, Javors MA.

J Anal Toxicol. 2012 Jan-Feb;36(1):66-8. doi: 10.1093/jat/bkr018.

42.

JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.

Ginsburg BC, Schulze DR, Hruba L, McMahon LR.

J Pharmacol Exp Ther. 2012 Jan;340(1):37-45. doi: 10.1124/jpet.111.187757. Epub 2011 Sep 30.

43.

The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.

Stewart JL, McMahon LR.

Br J Pharmacol. 2011 Sep;164(2b):655-66. doi: 10.1111/j.1476-5381.2011.01388.x.

44.

Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.

Singh H, Schulze DR, McMahon LR.

Psychopharmacology (Berl). 2011 Jun;215(4):665-75. doi: 10.1007/s00213-010-2162-7. Epub 2011 Jan 19.

45.

The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.

Cunningham CS, McMahon LR.

Eur J Pharmacol. 2011 Mar 1;654(1):47-52. doi: 10.1016/j.ejphar.2010.12.003. Epub 2010 Dec 21.

46.

Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.

McMahon LR.

Br J Pharmacol. 2011 Mar;162(5):1060-73. doi: 10.1111/j.1476-5381.2010.01116.x.

47.

Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection.

Javors MA, Sanchez JJ, McMahon LR.

J Chromatogr Sci. 2010 Jul;48(6):491-5.

48.

Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.

Stewart JL, McMahon LR.

J Pharmacol Exp Ther. 2010 Jul;334(1):347-56. doi: 10.1124/jpet.110.168435. Epub 2010 Apr 7.

49.

In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.

Giuffrida A, McMahon LR.

Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):90-103. doi: 10.1016/j.prostaglandins.2009.05.004. Epub 2009 Jun 10. Review.

50.

Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.

Beardsley PM, Thomas BF, McMahon LR.

Int Rev Psychiatry. 2009 Apr;21(2):134-42. doi: 10.1080/09540260902782786. Review.

PMID:
19367507

Supplemental Content

Loading ...
Support Center